Solid Biosciences Inc.

SLDB Healthcare Biotechnology

Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.

5.53 0.21 −3.66%
Market cap
$615.5M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
n/a
Altman Z
−2.87
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.74 6.14 13.10 13.82
Net Debt/EBITDA
4.92 3.81 6.63 6.48
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.36) (0.62) (0.43) (0.37)
Book value per Share
2.31 2.06 3.41 2.60
Free Cash Flow
(33.56) (54.03) (47.39) (52.74)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates